Are there any benefits of Betoptic® S (betaxolol HCl ophthalmic suspension) over other β-blockers in the treatment of glaucoma?
Are there any benefits of Betoptic® S (betaxolol HCl ophthalmic suspension) over other β-blockers in the treatment of glaucoma?
复制标题
与其他β受体阻滞剂相比,Betoptic® S(盐酸倍他洛尔眼用混悬剂)在治疗青光眼方面是否有任何优势?
DOI:
--
复制
发表时间:
2004
影响因子:
3.2
通讯作者:
G. Kural
中科院分区:
文献类型:
--
作者:
A. Yarangümeli;G. Kural
The cardioselective β-blocker, betaxolol, is an effective ocular antihypertensive agent. Its mode of action in lowering intraocular pressure is similar to that of the nonselective blockers, by suppressing the flow of aqueous humor. The most frequent adverse reaction to betaxolol is stinging upon administration, which is minimised by an ocular suspension with a similarly effective twofold reduced concentration (Betoptic® S, 0.25%). The extent of β1-adrenoceptor occupancy of topically applied betaxolol in the systemic circulation is less than that of the nonselective blockers and β2-receptor occupancy is negligible, providing a better safety profile in patients with cardiopulmonary disease. Experimental studies have revealed that the drug reaches the retina after topical administration and displays a voltage-dependent L-type calcium channel blocking activity, which probably allows betaxolol to improve retinal perfusion and to serve as a neuroprotective agent recommendable in various forms of glaucoma.
登录
查看更多内容
影响因子:
4.4
作者:
Wax,MB;Molinoff,PB;Alvarado,J;Polansky,J
通讯作者:
Polansky,J
影响因子:
4.4
作者:
Topper,JE;Brubaker,RF
通讯作者:
Brubaker,RF
影响因子:
13.7
作者:
Reiss,GR;Brubaker,RF
通讯作者:
Brubaker,RF
DOI:
10.1001/archopht.1981.03930010093010
发表时间:
1981
期刊:
Archives of ophthalmology (Chicago, Ill. : 1960)
影响因子:
--
作者:
Thomas,JV;Epstein,DL
通讯作者:
Epstein,DL
影响因子:
4.2
作者:
Robinson,JC;Kaufman,PL
通讯作者:
Kaufman,PL